kabutan

SymBio Pharmaceuticals Limited(4582) Summary

4582
TSE Growth
SymBio Pharmaceuticals Limited
107
JPY
-3
(-2.73%)
Mar 13, 3:30 pm JST
0.67
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
106.3
Mar 13, 11:34 pm JST
Summary Chart Historical News Financial Result
PER
PBR
7.41
Yield
ー%
Margin Trading Ratio
11,263.25
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
107 JPY 0.67 USD
Previous Close Mar 12
110 JPY 0.69 USD
High Mar 13, 9:00 am
108 JPY 0.67 USD
Low Mar 13, 10:16 am
105 JPY 0.65 USD
Volume
1,179,500
Trading Value
0.13B JPY 0.79M USD
VWAP
106.53 JPY 0.67 USD
Minimum Trading Value
10,700 JPY 67 USD
Market Cap
6.86B JPY 0.04B USD
Number of Trades
480
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Slightly High
1-Year Average
685
1-Year High Feb 20, 2026
28,273
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 5,784,500
Feb 27, 2026 1,000 6,626,900 6626.90
Feb 20, 2026 25,300 6,188,800 244.62
Feb 13, 2026 0 4,839,700
Feb 6, 2026 0 5,047,600
Company Profile
SymBio Pharmaceuticals Limited specializes in three areas: cancer, hematology, and pain management. The company also commercializes new drug candidates from other companies.
Sector
Pharmaceuticals
SymBio Pharmaceuticals Limited is a specialty pharmaceutical company focused on rare diseases, primarily in the fields of oncology, hematology, and viral infections. The company advances the development of compounds that have already established proof of concept in humans. Utilizing its unique discovery network and evaluation expertise, SymBio conducts initial screenings through its in-house specialist staff, followed by rigorous evaluations from experienced external experts before finalizing potential in-licensing candidates. By adopting a "labo-less fab-less" strategy to minimize fixed costs, the company concentrates on high-value-added activities while outsourcing routine development tasks. SymBio's pipeline includes drugs such as Treakisym, rigosertib, and brincidofovir, promoting new drug development in areas with high unmet medical needs. While the company has primarily focused its business operations in Japan and Asia, it now aims to expand globally to enhance its business value.